Johanna Kulpa1, Cathrin Skrabs1, Ralph Simanek1, Peter Valent1, Simon Panzer2, Klaus Lechner1, Christian Sillaber1, Ulrich Jäger3. 1. Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. 2. Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. 3. Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. ulrich.jaeger@meduniwien.ac.at.
Abstract
BACKGROUND: Primary warm autoimmune hemolytic anemia (WAIHA) is a rare autoimmune disorder frequently responding to corticosteroid first-line treatment and effective second-line treatment options such as splenectomy or anti-CD20 antibody therapy. Disease management is frequently hampered by a lack of evidence. METHODS: We have investigated the probability of sustained treatment-free remission after steroid induction to facilitate clinical decision making regarding timing and necessity of second-line treatments. Response data from 31 patients with primary WAIHA initially treated with steroids were retrospectively analyzed. All patients responded by achieving a hemoglobin of at least 10 mg/dl. RESULTS: After steroid tapering and final withdrawal, 9 of 30 patients remained in unsustained complete remission (CR). The probability of remaining in CR after steroid treatment only was 38.2 % (2 SD 20.6 %) at 15 months. The median remission duration was 100 + months with a range of 12 + to 163 + months. Of note, none of the remaining patients still on steroids achieved CR beyond 15 + months. CONCLUSION: These data indicate that a considerable proportion of patients do not need further treatment and that relapses will not occur after 15 months in CR.
BACKGROUND: Primary warm autoimmune hemolytic anemia (WAIHA) is a rare autoimmune disorder frequently responding to corticosteroid first-line treatment and effective second-line treatment options such as splenectomy or anti-CD20 antibody therapy. Disease management is frequently hampered by a lack of evidence. METHODS: We have investigated the probability of sustained treatment-free remission after steroid induction to facilitate clinical decision making regarding timing and necessity of second-line treatments. Response data from 31 patients with primary WAIHA initially treated with steroids were retrospectively analyzed. All patients responded by achieving a hemoglobin of at least 10 mg/dl. RESULTS: After steroid tapering and final withdrawal, 9 of 30 patients remained in unsustained complete remission (CR). The probability of remaining in CR after steroid treatment only was 38.2 % (2 SD 20.6 %) at 15 months. The median remission duration was 100 + months with a range of 12 + to 163 + months. Of note, none of the remaining patients still on steroids achieved CR beyond 15 + months. CONCLUSION: These data indicate that a considerable proportion of patients do not need further treatment and that relapses will not occur after 15 months in CR.
Entities:
Keywords:
Warm autoimmune hemolytic anemia; long term remission; steroids
Authors: Henrik Birgens; Henrik Frederiksen; Hans C Hasselbalch; Inge H Rasmussen; Ove J Nielsen; Lars Kjeldsen; Herdis Larsen; Torben Mourits-Andersen; Torben Plesner; Dorthe Rønnov-Jessen; Hanne Vestergaard; Tobias W Klausen; Claudia Schöllkopf Journal: Br J Haematol Date: 2013-08-24 Impact factor: 6.998
Authors: Mathilde Roumier; Valentine Loustau; Constance Guillaud; Laetitia Languille; Matthieu Mahevas; Mehdi Khellaf; Nicolas Limal; France Noizat-Pirenne; Bertrand Godeau; Marc Michel Journal: Am J Hematol Date: 2014-06-19 Impact factor: 10.047
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751